Based in Washington, DC, Danaher Corporation (DHR) stands out as a premier global innovator in life sciences and diagnostics, addressing many of the significant health challenges globally. The company is engaged in sectors including Life Sciences, Diagnostics, and Biotechnology, among others. Currently valued at approximately $145 billion in market capitalization, Danaher boasts a workforce of thousands and operates in over 50 countries across 700 locations worldwide.
The prominent healthcare firm is set to share its third-quarter earnings results on Tuesday, October 21, before the market opens. Analysts have predicted that Danaher will report an adjusted profit of $1.72 per share, representing a slight increase from $1.71 per share in the same quarter last year. The company has shown a varied earnings surprise history, missing bottom-line estimates once in the past four quarters while exceeding projections on three occasions.
-
When The Market Structure Breaks: How To Survive The Next Phase
-
Netflix Stock Still Looks 15% Too Cheap, Especially If It Keeps Producing 20% FCF Margins
-
Trade Tensions, Market Volatility and Other Key Things to Watch this Week
For the entirety of fiscal 2025, analysts expect DHR to report an adjusted EPS of $7.77, reflecting a 3.9% increase from $7.48 in 2024. Furthermore, projections for fiscal 2026 indicate a robust earnings growth of 9.9% year-over-year to reach $8.54 per share.
In the past 52 weeks, DHR’s stock has decreased by 24%, falling short of the Health Care Select Sector SPDR Fund’s (XLV) 7% decline and the S&P 500 Index’s ($SPX) returns of 13.4% during the same period.
Following the release of its strong second-quarter results on July 22, Danaher’s stock rose nearly 1% and maintained positive momentum for the next three trading sessions. The quarter was notably bolstered by impressive performance from its bioprocessing sector, contributing to a 3.4% increase in revenue year-over-year to $5.9 billion, which exceeded analysts’ expectations by 1.7%. Additionally, adjusted EPS for the quarter grew by 4.7% year-over-year to $1.80, surpassing consensus estimates by 9.8%.
Recent fluctuations in the DHR stock price are closely linked to changing healthcare policies from the Federal government; however, the longer-term outlook for the company remains optimistic.
Analysts maintain a strong bullish consensus on DHR stock, categorizing it as a “Strong Buy.” Out of 23 analysts, 18 suggest “Strong Buys,” one recommends a “Moderate Buy,” and four advise a “Hold” rating. The average price target of $240.75 indicates an expected upside of 18.9% from current levels.
At the time of publication, Aditya Sarawgi did not hold (directly or indirectly) any positions in the securities mentioned in this article. All information and data are intended for informational purposes only. This article was originally published on Barchart.com
